NNZ-2591 (cyclo-L-glycyl-L-2-allylproline) has not yet been allocated a generic name.
NNZ-2566 was named Trofinetide, and accepted by the WHO as its International Non-proprietary Name (INN) in 2015 (during the Ph2 trial).
Conversely, Ph2 trials for NNZ-2591 are expected to be completed in 2024, with the Ph2 Phelan-McDermid results published in December 2023.
As NEU prepares its FDA Ph2 submission, it's time for NNZ-2591 to be assigned a generic name.
- Forums
- ASX - By Stock
- NEU
- NNZ-2591 development & commercialisation
NNZ-2591 development & commercialisation, page-2
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$14.47 |
Change
-1.120(7.18%) |
Mkt cap ! $1.849B |
Open | High | Low | Value | Volume |
$15.38 | $15.40 | $14.40 | $9.160M | 624.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 50 | $14.46 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.55 | 1764 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 50 | 14.460 |
2 | 2041 | 14.450 |
3 | 8114 | 14.440 |
1 | 1732 | 14.430 |
1 | 400 | 14.420 |
Price($) | Vol. | No. |
---|---|---|
14.550 | 1764 | 2 |
14.610 | 2314 | 3 |
14.670 | 2041 | 1 |
14.690 | 1200 | 1 |
14.700 | 1983 | 1 |
Last trade - 16.10pm 02/09/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |